Please login to the form below

Not currently logged in
Email:
Password:

GLP-1

This page shows the latest GLP-1 news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

The Blincyto approval is based on results from the Phase 1/2 ‘205 study, an open-label, multicentre, single-arm trial which evaluated Blincyto in paediatric patients with relapsed or refractory ... Sales of Bydureon shrank 2% in the first half of 2018,

Latest news

More from news
Approximately 12 fully matching, plus 143 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    These efforts moved up a gear last year when Novo decided to enter into phase III trials with an oral GLP-1.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    like peptide-1 (GLP-1), a hormone that works independently of insulin to stimulate glucose release. ... Oramed - whose technology relies on encapsulating the peptide or protein and delivering it alongside enzyme inhibitors and permeation enhancers - has

  • Deal Watch November 2015 Deal Watch November 2015

    Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... 6, 546. Hanmi Pharmaceutical. Sanofi. Licence. Three diabetes

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    400. Inarcia therapeutics / Investors. Synthetic royalty rights. ICTA650 extended sub-cutaneous delivery of GLP-1 for T2DM.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142. Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics